Comparison of Two Point-of-Care Lipid Analyzers for Use in Global Cardiovascular Risk Assessments

Point of care Point-of-Care Testing
DOI: 10.1345/aph.1k688 Publication Date: 2008-04-16T01:41:51Z
ABSTRACT
Background: Point-of-care (POC) lipid testing is increasingly used in community-and office-based practice. Two analyzers commonly the US are CardioChek PA and Cholostech LDX. Both directly measure total cholesterol (TC) high-density lipoprotein (HDL-C), mandatory values calculating a Framingham Risk Score (FRS). The FRS turn informs clinician of need for lipid-modifying therapy degree therapeutic intensity. Objective: To compare performance Cholestech Methods: Staff members from Colorado Prevention Center were included study, with all having fasted 12 hours beforo testing. No medical history was obtained. A venous blood sample collected measurements conducted laboratory, 2 finger sticks obtained at that time analyzed immediately on-site using POC analyzers. Intraclass correlation coefficients (ICCs) determined each analyzer versus laboratory analysis, greater than 0.75 defined as Indicators excellent reproducibility. We then assessed how interanalyzer differences TC or HDL-C impacted categorization. Results: Thirty-four adults (aged 24-56 y) participated study. ICC between LDX standard exceeded 075 4 categories (TC, p = 0.96; HDL-C, 0.88; low-density cholesterol, ρ 0.87; triglycerides, 0.99). By contrast, only exceeding triglycerides (ρ 0.84). When applied FRS, misclassified fewer individuals (5 vs 21). Overall, provided correct category more frequently < 0.001; > 0.001). Limitations study include use products small size no known risk factors. This project does not prove superior accuracy either device, but reflects real-world comparison single center. Conclusions: demonstrated better reproducibility when compared gold analysis allowed accurate categorization FRS. Since results these have potential to impact treatment decisions, larger, prospective, comparative studies seem warranted.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (13)
CITATIONS (67)